Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States,
by from Morbidity and Mortality Weekly Report (MMWR) on (#6E4QD)
This report describes the Advisory Committee on Immunization Practices' recommendation for using nirsevimab for infants and children to prevent severe respiratory syncytial virus disease.